Potential anti-TNF response biomarker identified
Friday, June 13, 2014 - 11:41
in Health & Medicine
DNA methylation has been identified as a potential biomarker of response to etanercept and adalimumab in patients with rheumatoid arthritis according to preliminary results from one of the largest methylome-wide investigations of treatment response to anti-TNF therapies. This data bring clinicians a step closer to being able to personalize a patient's treatment pathway.